Corporate Partnership
R&D Studies // Clinical Trials
We bring together biostatistics and bioinformatic expertise in the design, analysis & reporting of both exploratory studies and full-scale clinical trials for med-tech research. To provide a more comprehensive service for our clients, we seek to partner with compatible service providers such as full or partial-service CROs, and software firms.
So who are our clients?
Our clients consist of med-tech SMEs and start-ups from around the globe who are looking to conduct R&D or clinical trials to progress their clinical product to market.
Partnerships Agreements
Partnership with Anatomise Biostats can mutually enhance service provision to the client. Service proposals can be made more comprehensive and their delivery can be streamlined, simplifying processes for the client. Partners benefit from a reduction in the cost and duration of client acquisition activities, such as marketing and sales, by sharing clients through the multi-partner network. Partnership agreements may also enable packaging together of services that results in a reduced cost for the client.
Types of partnership agreements
Partnerships with us can be established on either a collaborative or referral basis:
- Referral partnerships: can be mutually beneficial and attract a referral fee of around 15%.
- Collaborative partnerships are mutually beneficial and do not attract a referral fee.
Who do we collaborate with?
We partner with full-service CROs and other complementary service and technology companies to provide a more comprehensive service package to our clients. If you would like more information about how this might work for your company please contact us.
Collaborative partnerships
Collaborative partnerships aim to provide mutual clients with a more holistic service throughout all stages of the project lifecycle. This is achieved by pooling the distinct knowledge, resources and experience, while allowing each entity to remain focused and dedicated to delivering in their own area of expertise. Such collaborations are designed to be mutually beneficial to all parties and facilitate the operational growth of all using shared resources.
Partnership agreements for CROs
A collaborative partnership with Anatomise Biostats allows CROs to leverage the highly specialised biostatistics and bioinformatics knowledge to better tailor and package services to specific clients. We offer both biostatistics and omics/bioinformatics expertise across multiple clinical sub-niches which can be combined over a single project or spread over multiple projects. CROs also benefit from an enhanced ability to expedite personalised medicine-based therapies by including master protocols in the case of biomarker-guided clinical trials or drug development ventures.
Referral partnerships
Referral partnerships have a similar aim as collaborative partnerships in terms of benefits to the client. To partners they offer:
- a potential of an additional income stream in the case of outgoing referrals
- a reduced cost of client acquisition in the case of incoming referrals.
Other benefits include:
- Complimentary listing on our website, which includes a large logo and one paragraph description of the partnering company.
- Social media coverage.
Referrals from existing clients
As a small business we rely on word of mouth. If you know someone who could benefit from our biostatistics consulting services, simply send them our way and let them know to mention your name when they contact us. Once they become a client, we will automatically apply a 10% discount to your next project as a thank you for your referral. Thank you for your continued support and we look forward to working with you and your referrals soon!
ProtoQSAR-MolDrug is specialized in the design, optimization, valorization, and development of new compounds (small molecules, peptides, nanomaterials, mixtures…) through Machine Learning-powered chemoinformatics and structural bioinformatics (QSARs, molecular docking, molecular dynamics, etc.).
Tools allow for the prediction and assessment of physicochemical, biological, pharmacological, and/or (eco)toxicological properties of substances with an array of advantages: (1) faster results, (2) saving of material and financial resources, (3) reduced animal testing (3Rs), (4) regulatory validity.
Research Domains: chemistry and regulatory toxicology and compound discovery and development for biotech, pharma, veterinary, cosmetics, nutraceuticals and agri-food industry.